Immunomodulators: Therapeutic Needs, Pipelines & Prospects

Published by: Business Insights

Published: Aug. 1, 2007 - 345 Pages

Table of Contents

Immunomodulators: Therapeutic needs, Pipelines & Prospects

Executive Summary

Modulating the immune system

Inflammatory and Autoimmune Disorders

Infectious disease

Cancer

Transplantation

Market Considerations and Forecasts

Trends and Opportunities

Chapter 1 Modulating the immune system

Summary

Introduction

Overview of the human immune system

Innate (non-specific) immunity

Cytokines: the chemical messengers

Lipid mediators of inflammation

Phagocytic and natural killer cells

Complement system

Inflammatory and acute phase responses

Adaptive (specific) immunity

B and T lymphocytes

Antigen-presenting cells

Biopharmaceuticals as immunomodulators

Delivery of biopharmaceuticals

Regulatory requirements (US)

Scope of this Report

Chapter 2 Inflammatory and Autoimmune Disorders

Summary

Introduction

The role of T cells in autoimmune diseases and allergies

Current therapies

Glucocorticoids

Nonsteroidal anti-inflammatory drugs

Nitric oxide (NO)-releasing NSAIDs

Therapies targeting proinflammatory cytokines

B cell-targeted therapeutics

Other therapies

Current drug targets

GPCRs

Chemokine receptors

LTB4 receptor

S1P1 receptor

Leukocyte surface antigens

Cytokines and their receptors

IL-1 and receptors

Other ILs and receptors

TNF proteins and receptors

BlyS (BAFF) and APRIL

Interferons

Other cytokines

Kinases

Other targets

Immunomodulators in clinical development (US)

Rheumatoid arthritis

Psoriasis

Multiple sclerosis

Inflammatory bowel disease

Systemic lupus erythematosus

Asthma and allergic rhinitis

Chronic obstructive pulmonary disease

Cardiovascular disease

Chapter 3 Infectious Disease

Summary

Introduction

Types of vaccines

Combination vaccines

Viruses

Influenza

New vaccines

HIV

New vaccines

Other immunotherapies

Hepatitis viruses

New vaccines

Other immunotherapies

Herpes simplex viruses

New vaccines

RSV

New vaccines and immunotherapies

Bacteria, fungi and parasites

New vaccines

Other immuotherapies

Chapter 4 Cancer

Summary

Overview of Cancer

Tumor immunity

Treatment of cancer

Overview of immunotherapies

Small molecule immunomodulators

Cytokines

Monoclonal antibodies

Recent trends

Prophylactic vaccines

Therapeutic vaccines

Tumor antigens targeted by vaccines

Antigen/adjuvant vaccines

Whole cell vaccines

Dendritic cell vaccines

Idiotype vaccines

Genetically-engineered vaccines

Immunostimulatory sequences

Adoptive T cell immunity

Chapter 5 Transplantation

Summary

Introduction to organ transplantation

Rejection mechanisms

Prevention of rejection

Small molecule immunosuppressants

Calcineurin inhibitors

Anti-proliferatives

Glucocorticoids

mTOR inhibitors

Novel small molecule drugs

Induction therapy with T cell antibodies

Polyclonal antibodies

Monoclonal antibodies and fusion proteins

Co-stimulatory blockers

New approaches to prevention of GVHD

Chapter 6 Market Considerations and Forecasts

Summary

Introduction

Overview of the AIID Market

Rheumatoid arthritis

Multiple sclerosis

Inflammatory bowel disease

Systemic lupus erythematosus

Psoriasis

Asthma and allergic rhinitis

Overview of the Viral Infectious Disease Market

Influenza

HIV

Hepatitis viruses

Herpes simplex viruses

RSV

Overview of the Cancer Market

Cytokines

Monoclonal antibodies

Prophylactic vaccines

Therapeutic vaccines

Overview of the Transplantation Market

Quantitative Market Analysis

The global pharmaceutical market

The global immunomodulator market

Immunosuppression in AIID and allergies

Vaccines for viral pathogens

Vaccines for cancer

Monoclonal antibodies for cancer

Recombinant interferons

Transplantation medicine

Geographical analysis

Chapter 7 Trends and Opportunities

Summary

Preclinical immunomodulator programs

Trends in vaccines

Trends in monoclonal antibodies

Future players in immunomodulation

Immunomodulators Patent Survey

Patenting Activity

Leading assignees

Patent citation analysis

Appendix

Research Methodology

Index

List of Figures

Figure 7.1: Immunomodulators - Drug origins

List of Tables

Table 1.1: Immunomodulators Summary

Table 1.2: Indications by Category and Within-Category Count

Table 1.3: Recent Immunomodulator Deals

Table 2.4: Immunomodulators in US Clinical Development (Rheumatoid Arthritis)

Table 2.5: Immunomodulators in US Clinical Development (Psoriasis)

Table 2.6: Immunomodulators in US Clinical Development (Multiple Sclerosis)

Table 2.7: Immunomodulators in US Clinical Development (Crohn's Disease)

Table 2.8: Immunomodulators in US Clinical Development (Ulcerative Colitis)

Table 2.9: Immunomodulators in US Clinical Development (SLE)

Table 2.10: Immunomodulators in US Clinical Development (Asthma)

Table 2.11: Immunomodulators in US Clinical Development (Allergic Rhinitis)

Table 2.12: Immunomodulators in US Clinical Development (COPD)

Table 2.13: Immunomodulators in US Clinical Development (General Inflammation)

Table 2.14: Immunomodulators in US Clinical Development (Autoimmune Disorders)

Table 3.15: Immunomodulators in US Clinical Development (Influenza)

Table 3.16: Immunomodulators in US Clinical Development (HIV)

Table 3.17: Immunomodulators in US Clinical Development (Viral Hepatitis)

Table 3.18: Immunomodulators in US Clinical Development (Herpes simplex)

Table 3.19: Immunomodulators in US Clinical Development (Other Viruses)

Table 3.20: Immunomodulators in US Clinical Development (Bacteria, Fungi, and Parasites)

Table 4.21: Immunomodulators in US Clinical Development (Breast cancer)

Table 4.22: Immunomodulators in US Clinical Development (Prostate cancer)

Table 4.23: Immunomodulators in US Clinical Development (Non-Small Cell Lung Cancer)

Table 4.24: Immunomodulators in US Clinical Development (Ovarian cancer)

Table 4.25: Immunomodulators in US Clinical Development (Malignant melanoma)

Table 4.26: Immunomodulators in US Clinical Development (Head and neck cancer)

Table 4.27: Immunomodulators in US Clinical Development (Pancreatic cancer)

Table 4.28: Immunomodulators in US Clinical Development (Renal cancer)

Table 4.29: Immunomodulators in US Clinical Development (Solid tumours)

Table 4.30: Immunomodulators in US Clinical Development (Lymphoma)

Table 4.31: Immunomodulators in US Clinical Development (Non-Hodgkin's Lymphoma)

Table 4.32: Immunomodulators in US Clinical Development (Multiple myeloma)

Table 4.33: Immunomodulators in US Clinical Development (General Cancer)

Table 4.34: Immunomodulators in US Clinical Development (Colorectal cancer)

Table 4.35: Immunomodulators in US Clinical Development (Chronic Lymphocytic Leukaemia)

Table 4.36: Glossary - Immunomodulators in US Clinical Development

Table 5.37: Immunomodulators in US Clinical Development (Transplantation)

Table 6.38: World Population Data (2006)

Table 6.39: Inflammatory Disease Prevalences and Incidences (2006)

Table 6.40: Inflammatory Disease Summary (2006)

Table 6.41: World AIDS Statistics (2006)

Table 6.42: World Annual Cancer Incidence by Site (2002)

Table 6.43: Trends in cancer incidence, 1975-2000

Table 6.44: World Cancer Statistics (2002)

Table 6.45: World Pharma Market by Therapeutic Category, 2006-2011

Table 6.46: World Pharma Market by Region, 2006-2011

Table 6.47: Immunomodulator Analysis by Therapy Type (2006-2011)

Table 6.48: Immunomodulator Analysis by Indication (2006-2011)

Table 6.49: World Immunomodulator Market by Region, 2006-2011

Table 7.50: Preclinical Immunomodulators by Indication

Table 7.51: Preclinical Vaccines: Therapy Types

Table 7.52: Preclinical Vaccines: Top Indications

Table 7.53: Monoclonal antibodies in preclinical development

Table 7.54: Preclinical Immunomodulators: Top Originators

Table 7.55: Preclinical Vaccines: Top Originators

Table 7.56: Immunomodulator Patent Survey: Category Definitions

Table 7.57: Summary of Patents by Segment

Table 7.58: US Immunomodulator Patents: Filing and Publication Activity, 1992-2007 (All Patents)

Table 7.59: US Immunomodulator Patents: Filing and Publication Activity, 1992-2007 (Autoimmunity)

Table 7.60: US Immunomodulator Patents: Filing and Publication Activity, 1992-2007 (Allergy)

Table 7.61: US Immunomodulator Patents: Filing and Publication Activity, 1992-2007 (General Immunotherapy)

Table 7.62: US Immunomodulator Patents: Filing and Publication Activity, 1992-2007 (Transplantation)

Table 7.63: US Immunomodulator Patents: Filing and Publication Activity, 1992-2007 (Vaccines)

Table 7.64: US Immunomodulator Patents: Assignee Summary

Table 7.65: US Immunomodulator Patents: Top Assignees

Table 7.66: US Immunomodulator Patents: Most Frequenty Cited Organizations

Table 7.67: Top-Cited Immunomodulator Patents, Entire Data Set (US Filings, 1992-2007)

Abstract

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.